<DOC>
	<DOCNO>NCT01891019</DOCNO>
	<brief_summary>The objective study obtain information effectiveness thalidomide psoriasis .</brief_summary>
	<brief_title>Thalidomide Treatment Chronic Plaque Psoriasis .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Male female subject 18 year age old . Stable worsen psoriasis involve 5 % great total body surface area ( BSA ) involvement minimum PASI score 8 . Moderate severe plaquetype psoriasis , define minimum score 1 erythema , scaling , plaque thickness ( use 0 4 scale ) . Patients receive systemic retinoids , prednisone , methotrexate , cyclosporine stable dose least 28 day prior first dose thalidomide . Patients receive topical treatment consistent treatment throughout study . The ability willingness follow study procedure , attend schedule visit , successfully complete study . The ability understand sign write informed consent form , must obtain prior treatment . The ability understand , agree , comply requirement System Thalidomide Education Prescribing Safety ( S.T.E.P.S. ) . ** ( *Because know teratogenic effect thalidomide effort prevent great extent possible chance fetal exposure thalidomide , THALOMID ( thalidomide ) approve market special restricted distribution program approve FDA . Under program , System Thalidomide Education Prescribing Safety ( S.T.E.P.S . ) , prescribers pharmacist register program allow prescribe dispense thalidomide ( Zeldis JB et al . 1999 ) . In addition , patient must advise , agree , comply requirement S.T.E.P.S . Program . To monitor patient compliance S.T.E.P.S . program , patient must complete S.T.E.P.S . program inform consent participate mandatory confidential surveillance registry . ) Unstable psoriasis Unable unwilling meet criterion contraception require STEPS . Known allergy thalidomide . Known history neuropathy . Abnormal laboratory test result investigator feel would compromise patient safety evaluation drug safety . The introduction drug medical condition know affect psoriasis ( e.g. , lithium , betaadrenergic blocker , etc . ) period 4 week prior study period . Use investigational therapy within 4 week prior first dose thalidomide . Expectation exposure strong sunlight course study ( e.g . plan holiday high sunlight area ) intention sunbathe prolonged period time course study . Current drug alcohol abuse ( drug screening require ) . Medical condition preclude thalidomide therapy . Any condition , judgment investigator , would put subject unacceptable risk participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>